## IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A sodium channel blocker represented by the general structure:

$$R_{5}$$
 $R_{6}$ 
 $R_{2}$ 
 $R_{6}$ 
 $R_{2}$ 

wherein R is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>-alkyl, C<sub>1</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> alky, C<sub>8</sub>-C<sub>12</sub> alkyl, C<sub>2</sub>-C<sub>9</sub> alkenyl, C<sub>2</sub>-C<sub>9</sub> alkynyl, -(CH<sub>2</sub>)<sub>m</sub>COOH, -(CH<sub>2</sub>)<sub>m</sub>NH<sub>2</sub>, -(CH<sub>2</sub>)<sub>m</sub>CONH<sub>2</sub>, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>aryl, -(CH<sub>2</sub>)<sub>n</sub>substituted aryl, -(CH<sub>2</sub>)<sub>p</sub>NCH<sub>3</sub>(CH<sub>2</sub>)<sub>p</sub>substituted aryl and -(CH<sub>2</sub>)<sub>n</sub>substituted heterocyclic, wherein m is an integer ranging from 3-8, n is an integer ranging from 0-4 and p is an integer ranging from 1-4;

 $R_2$  is selected from the group consisting of -(CH<sub>2</sub>)<sub>n</sub>COOH, -(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, and -(CH<sub>2</sub>)<sub>n</sub>CONHR<sub>10</sub>; with the proviso that when  $R_2$  is -(CH<sub>2</sub>)<sub>n</sub>CONHR<sub>10</sub>, n is 3 or 4;

R<sub>3</sub> is selected from the group consisting of hydroxy, amino, C<sub>1</sub>-C<sub>4</sub> alkoxy,
-CH<sub>2</sub>OH and -CONH<sub>2</sub>, or R<sub>2</sub> and R<sub>3</sub> taken together with the atoms to which they are attached form an optionally substituted a heterocyclic ring;

 $R_4$  and  $R_5$  are independently selected from the group consisting of H, halo,  $C_1$ - $C_4$  alkyl,  $C_2$ - $C_4$  alkenyl,  $C_2$ - $C_4$  alkynyl, and  $C_1$ - $C_4$  alkoxy; and

R<sub>6</sub> is selected from the group consisting of H, C<sub>1</sub>-C<sub>8</sub> alkyl,

wherein R<sub>7</sub> and R<sub>8</sub> are independently selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl and C<sub>2</sub>-C<sub>4</sub> alkynyl, and R<sub>9</sub> is H, or R<sub>8</sub> and R<sub>9</sub> taken together with the atoms to which

they are attached form an optionally substituted  $\underline{a}$  heterocyclic ring, and  $R_{10}$  is selected from the group consisting of H, benzyl and  $C_1$ - $C_4$  alkyl, with the proviso that when  $R_2$  and  $R_3$  taken together form a heterocyclic ring, R is not -(CH<sub>2</sub>)<sub>n</sub>aryl.

- 2. (Original) The compound of claim 1, wherein  $R_2$  is -(CH<sub>2</sub>)<sub>n</sub>CONH<sub>2</sub>; and  $R_3$  is hydroxyl.
- 3. (Withdrawn) The compound of claim 1, wherein  $R_2$  and  $R_3$  taken together with the atoms to which they are attached form a heterocyclic ring having the structure:

$$O$$
 $R$ 
 $N$ 
 $O$ 
 $R$ 
 $R$ 

wherein X is selected from the group consisting of -CHR<sub>12</sub>-, -O- and -NR<sub>12</sub>-, wherein  $R_{11}$  and  $R_{12}$  are independently selected from the group consisting of H, benzyl and  $C_1$ - $C_4$  alkyl.

- 4. (Currently Amended) The compound of claim 2 or 3 wherein R is selected from the group consisting of  $C_4$ - $C_{12}$ -alkyl,  $C_1$  alkyl,  $C_3$ - $C_6$  alky,  $C_8$ - $C_{12}$  alkyl,  $C_2$ - $C_8$  alkenyl and  $C_2$ - $C_8$  alkynyl.
- 5. (Currently Amended) The compound of claim 2 or 3 wherein  $R_4$  and  $R_5$  are independently selected from the group consisting of H, halo and  $C_1$ - $C_4$  alkyl; and

R<sub>6</sub> is selected from the group consisting of H,

wherein n is an integer ranging from 0-2.

- 6. (Original) The compound of claim 5 wherein  $R_4$  and  $R_6$  are both H, and  $R_5$  is Cl or F.
  - 7. (Original) The compound of claim 5 wherein R<sub>4</sub> and R<sub>5</sub> are both H, and R<sub>6</sub> is

wherein n is an integer ranging from 0-2.

8. (Original) The compound of claim 5 wherein  $R_4$  and  $R_5$  are both  $C_1\text{-}C_4$  alkyl, and  $R_6$  is

wherein n is an integer ranging from 0-2.

9. (Currently Amended) The compound of claim 2-or 3 wherein R is

$$CH_3$$
  $CH_3$   $CH_3$ 

 $R_4$  and  $R_5$  are independently selected from the group consisting of H, halo and  $C_1\text{-}C_4$  alkoxy; and

R<sub>6</sub> is H.

10. (Currently Amended) A pharmaceutical composition comprising a compound represented by the general formula:

$$R_{5}$$
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 

wherein R is selected from the group consisting of  $C_1$ - $C_{12}$ -alkyl,  $C_1$  alkyl,  $C_3$ - $C_6$  alky,  $C_8$ - $C_{12}$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-C<sub>6</sub> cycloalkyl,

$$CH_3$$
  $CH_3$   $CH_3$   $CH_3$   $CH_3$   $CH_3$   $CH_3$   $CH_3$   $CH_3$ 

wherein n is an integer ranging from 0-4;

 $R_2$  is H or  $C_1$ - $C_4$  alkyl;

 $R_4$  and  $R_5$  are independently selected from the group consisting of H, halo,  $C_1$ - $C_4$  alkyl,  $C_2$ - $C_4$  alkenyl,  $C_2$ - $C_4$  alkynyl, -COR<sub>11</sub> and ( $C_1$ - $C_4$ ) alkoxy; and

R<sub>6</sub> is selected from the group consisting of H, halo,

wherein R<sub>11</sub> is selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl, NH<sub>2</sub> and OH; and a pharmaceutically acceptable carrier.

11. (Original) The composition of claim 10 further comprising an anti-tumor agent.

- 12. (Original) The composition of claim 11, wherein the anti-tumor agent is a chemotherapeutic.
- 13. (Currently Amended) The composition of claim 10, wherein R is selected from the group consisting of  $C_1$ - $C_{12}$ -alkyl,  $C_1$  alkyl,  $C_3$ - $C_6$  alky, and  $C_8$ - $C_{12}$  alkyl;

 $R_4$  and  $R_5$  are independently selected from the group consisting of H, halo and  $C_1\text{-}C_4$  alkyl; and

R<sub>6</sub> is selected from the group consisting of H,

wherein n is an integer ranging from 0-4.

14. (Currently Amended) A method of specifically inhibiting voltage-gated sodium channels, said method comprising the step of contacting said sodium channel with a compound represented by the general structure:

$$R_{5}$$
 $R_{6}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 

wherein R is selected from the group consisting of  $C_1$ - $C_{12}$ -alkyl,  $C_1$  alkyl,  $C_3$ - $C_6$  alky,  $C_8$ - $C_{12}$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>- $C_6$  cycloalkyl,

 $R_4$  and  $R_5$  are independently selected from the group consisting of H, halo,  $C_1$ - $C_4$  alkyl,  $C_2$ - $C_4$  alkenyl,  $C_2$ - $C_4$  alkynyl, -COR<sub>11</sub> and ( $C_1$ - $C_4$ ) alkoxy; and

R<sub>6</sub> is selected from the group consisting of H, halo,

wherein  $R_{11}$  is selected from the group consisting of H,  $C_1$ - $C_4$  alkyl,  $NH_2$  and OH, and n is an integer ranging from 0-4.

15. (Currently Amended) The method of claim 14 wherein R is selected from the group consisting of  $C_1$ - $C_{12}$ -alkyl,  $C_1$  alkyl,  $C_3$ - $C_6$  alky, and  $C_8$ - $C_{12}$  alkyl;

 $R_4$  and  $R_5$  are independently selected from the group consisting of H, halo and  $C_1\text{-}C_4$  alkyl; and

R<sub>6</sub> is selected from the group consisting of H,

wherein n is an integer ranging from 0-4.

16. (Withdrawn) A method for treating a neoplastic disease, said method comprising the step of administering to a patient in need thereof a composition comprising a compound represented by the general structure:

$$R_{5}$$
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 
 $R_{6}$ 

wherein R is selected from the group consisting of  $C_1$ - $C_{12}$  alkyl,  $C_2$ - $C_8$  alkenyl,  $C_2$ - $C_8$  alkynyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-C<sub>6</sub> cycloalkyl,

wherein n is an integer ranging from 0-4;

 $R_4$  and  $R_5$  are independently selected from the group consisting of H, halo,  $C_1$ - $C_4$  alkyl,  $C_2$ - $C_4$  alkenyl,  $C_2$ - $C_4$  alkynyl, -COR<sub>11</sub> and ( $C_1$ - $C_4$ ) alkoxy; and

R<sub>6</sub> is selected from the group consisting of H, halo,

wherein R<sub>11</sub> is selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl, NH<sub>2</sub> and OH.

17. (Withdrawn) The method of claim 16 wherein R is selected from the group consisting of  $C_1$ - $C_{12}$  alkyl;

 $R_4$  and  $R_5$  are independently selected from the group consisting of H, halo and  $C_1\text{-}C_4$  alkyl; and

R<sub>6</sub> is selected from the group consisting of H,

wherein n is an integer ranging from 0-4.

- 18. (Withdrawn) The method of claim 17 wherein  $R_4$  and  $R_5$  are independently selected from the group consisting of H and halo; and  $R_6$  is H.
- 19. (Currently Amended) A sodium channel blocker represented by the general structure

$$R_{5}$$
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 

wherein R<sub>4</sub> and R<sub>5</sub> are independently selected from the group consisting of H, halo and C<sub>1</sub>-C<sub>4</sub> alkyl;

Attorney Docket No. 00769-07 Patent Application Serial No. 10/511,666 Response to 8/10/07 Office Action

R<sub>6</sub> is selected from the group consisting of H,

wherein n is an integer ranging from 0-4 and

 $R_{14}$  and  $R_{15}$  are independently selected from the group consisting of H and halo, or  $R_{14}$  and  $R_{15}$  taken together with the atoms to which they are attached form an optionally substituted  $C_5$ - $C_6$ -aryl.

20. (Canceled)